Vivoryon Therapeutics N.V. Logo

Vivoryon Therapeutics N.V.

Developing first-in-class small molecule therapies for age-related and kidney diseases.

VVY | AS

Overview

Corporate Details

ISIN(s):
NL00150002Q7
LEI:
3912004AMB0KGZXZYJ15
Country:
Germany
Address:
Weinbergweg 22, 06120 Halle (Saale)
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class, small molecule-based therapies for age-related diseases. The company leverages its in-depth expertise in post-translational modifications to develop medicines that modulate the activity and stability of proteins altered in disease. Its most advanced candidate, varoglutamstat, is an orally administered inhibitor of glutaminyl cyclases (QPCT and QPCTL), enzymes implicated in causing or promoting inflammatory, fibrotic, and neurodegenerative diseases, with a primary focus on kidney diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 07:28
Interim Report
Vivoryon Therapeutics N.V., Halfjaarlijkse financiële verslaggeving
English 1.3 MB
2025-08-21 14:00
Regulatory News Service
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT)…
English 7.6 KB
2025-06-27 07:36
Report Publication Announcement
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
English 649.6 KB
2025-06-17 07:52
Earnings Release
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
English 716.2 KB
2025-06-11 07:44
Report Publication Announcement
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational …
English 650.9 KB
2025-06-06 10:30
Regulatory News Service
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND …
English 654.5 KB
2025-06-05 14:00
Regulatory News Service
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Dis…
English 8.8 KB
2025-05-27 07:44
Regulatory News Service
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S…
English 686.4 KB
2025-04-29 07:02
Annual Report
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
English 10.7 MB
2025-04-25 07:42
Capital/Financing Update
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
English 656.2 KB
2025-02-11 18:12
Report Publication Announcement
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on Febr…
English 629.7 KB
2024-12-10 07:49
Earnings Release
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on V…
English 674.7 KB
2024-11-20 17:07
Earnings Release
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
English 2.0 MB
2024-10-28 07:39
Earnings Release
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutam…
English 722.2 KB
2024-10-11 16:18
Regulatory News Service
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the Ame…
English 222.8 KB

Automate Your Workflow. Get a real-time feed of all Vivoryon Therapeutics N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Vivoryon Therapeutics N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-04-01 E. Platzer Executive member Buy 123,809 1,299,994.50 EUR
2022-04-01 U. Dauer Executive member Buy 4,761 49,990.50 EUR
2020-12-02 D.J. von der Osten Executive member Buy 20,000 112,400.00 EUR
2020-11-30 M. Schaeffer Executive member Other 3,867 N/A

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.